A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—To assess efficacy and tolerability of insulin detemir or NPH insulin added to oral therapy for type 2 diabetes in a treat-to-target titration protocol. RESEARCH DESIGN AND METHODS—Individuals (n = 476) with HbA1c (A1C) 7.5–10.0% were randomized to addition of twice-daily insulin detemir or NPH insulin in a parallel-group, multicenter trial. Over 24 weeks, insulin doses were titrated toward prebreakfast and predinner plasma glucose targets of ≤6.0 mmol/l (≤108 mg/dl). Outcomes assessed included A1C, percentage achieving A1C ≤7.0%, risk of hypoglycemia, and body weight. RESULTS—At 24 weeks, A1C had decreased by 1.8 and 1.9% (from 8.6 to 6.8 and from 8.5 to 6.6%) for detemir and NPH, respectively (NS). In both groups, 70% of participants achieved an A1C ≤7.0%, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 vs. 16%, P = 0.008). Compared with NPH insulin, the risk for all hypoglycemia with insulin detemir was reduced by 47% (P < 0.001) and nocturnal hypoglycemia by 55% (P < 0.001). Mean weight gain was 1.2 kg with insulin detemir and 2.8 kg with NPH insulin (P < 0.001), and the difference in baseline-adjusted final weight was −1.58 (P < 0.001). CONCLUSIONS—Addition of basal insulin to oral drug therapy in people with suboptimal control of type 2 diabetes achieves guideline-recommended A1C values in most people with aggressive titration. Insulin detemir compared with NPH insulin achieves this with reduced hypoglycemia and less weight gain.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The decrease in A1C from triple therapy was greater at 6 months than that of conventional therapy and the superiority was maintained at 3 years.1061”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1061]
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Glycemic Control From 1988 to 2000 Among U.S. Adults Diagnosed With Type 2 Diabetes
Koro, C. E., Bowlin, S. J., Bourgeois, N., & Fedder, D. O. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.17 · Cited by 648
Research works printed but not linked: 1
- Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 66:193–201, 2004 · DOI · Paper page
Cited by
Items 301–400 of 627
Management of diabetes across the course of disease: minimizing obesity-associated complications
Apovian, C. M. (2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s24022 · Cited by 14
Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes
Heintjes, E. M., Thomsen, T. L., Beest, F. J. A. P., Christensen, T., & Herings, R. M. C. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0020-y · Cited by 14
Lower severe hypoglycemia risk: insulin glargine versus NPH insulin in type 2 diabetes.
DAILEY, G. E., & Strange, P. (2008) · PubMed · Cited by 14
Schwartz, S. S., & Herman, M. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1043182 · Cited by 14
Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes
Juurinen, L., Tiikkainen, M., Saltevo, J. T., Nikkilä, K., Lanki, H., Leppävuori, E., Kock, T., Teikari‐Myyrä, T., Kauppinen‐Mäkelin, R., Kotronen, A., et al. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02691.x · Cited by 14
Rossiyskiy konsensus po terapii sakharnogo diabeta u detey i podrostkov
Dedov, I. I., Peterkova, V. A., & Кураева, Т. Л. (2010) · Diabetes Mellitus · doi:10.14341/2072-0351-6048 · Cited by 14
Vähätalo, M., Rönnemaa, T., & Viikari, J. S. A. (2007) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813430701507719 · Cited by 15
Impact of therapeutic advances on hypoglycaemia in type 2 diabetes
Boyle, P. J., & Zrebiec, J. F. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.795 · Cited by 14
Swinnen, S. G. H. A., & DeVries, J. H. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.02.009 · Cited by 14
The design of the liraglutide clinical trial programme
Nauck, M. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2012.01573.x · Cited by 14
Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin
Fießelmann, A., Wiesner, T., Fleischmann, H., & Bramlage, P. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0862-0 · Cited by 14
Grunberger, G., Chen, L., Rodríguez, Á., Tinahones, F. J., Jacober, S. J., Bue‐Valleskey, J. M., & on behalf of the IMAGINE 6 Investigators (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12743 · Cited by 13
Kinetics of Phenol Escape from the Insulin R6 Hexamer
Antoszewski, A., Lorpaiboon, C., Strahan, J., & Dinner, A. R. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c06544 · Cited by 15
Hahr, A. J., & Molitch, M. E. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2009.12.009 · Cited by 16
Drab, S. R. (2009) · Journal of the American Pharmacists Association · doi:10.1331/japha.2009.08181 · Cited by 13
Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review
JENDLE, J. H., Martin, S., & Miličević, Z. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.707190 · Cited by 13
Shah, S. N., Sharma, S. K., Singh, P., Muruganathan, A., & Das, A. K. (2014) · PubMed · Cited by 15
Hermansen, K., Lund, P., Clemmensen, K., Breum, L., Møller, M. K., Rosenfalck, A. M., & Christiansen, E. (2007) · The Review of Diabetic Studies · doi:10.1900/rds.2007.4.89 · Cited by 13
Self-citationControversies for Glucose Control Targets in Type 2 Diabetes: Exposing the Common Ground
Home, P. D. (2019) · Diabetes Care · doi:10.2337/dci19-0002 · Cited by 13
Self-citationKuritzky, L. (2006) · PubMed · Cited by 15
Practical strategies to improve treatment of type 2 diabetes
Fleury‐Milfort, E. (2008) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2008.00323.x · Cited by 15
Schmid, C., Krayenbühl, P., & Wiesli, P. (2009) · Diabetologia · doi:10.1007/s00125-009-1534-1 · Cited by 13
Tschöpe, D., Bramlage, P., Schneider, S., & Gitt, A. K. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115610470 · Cited by 12
Arakaki, R. F., Blevins, T., Wise, J. K., Liljenquist, D. R., Jiang, H. H., Jacobson, J. G., Martin, S., & Jackson, J. A. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12242 · Cited by 13
Segal, A. R., Vootla, T., & Beaser, R. S. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.009 · Cited by 14
Biocatalyzed synthesis of antidiabetic drugs: A review
Alcántara, C., & Alcántara, A. R. (2017) · Biocatalysis and Biotransformation · doi:10.1080/10242422.2017.1323887 · Cited by 14
Insulin analogs versus human insulin in type 2 diabetes
Migdalis, I. N. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70023-7 · Cited by 15
Morales, C., de Luis, D. A., de Arellano, A. R., Ferrario, M. G., & Lizán, L. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0143-x · Cited by 13
Johansen, O. E., Vanberg, P. J., Kilhovd, B. K., & Jørgensen, A. P. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3884 · Cited by 13
Basal insulins: Pharmacological properties and patient perspectives
Abrahamson, M. J. (2010) · Primary care diabetes · doi:10.1016/s1751-9918(10)60005-8 · Cited by 12
Intensive Diabetes Therapy and Body Weight: Focus on Insulin Detemir
Bush, M. A. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(07)80006-5 · Cited by 14
Edwards, K. L., Álvarez, C. A., Irons, B. K., & Fields, J. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.506 · Cited by 12
Insulin therapy for type 2 diabetes: premixed or basal-prandial?
Halbron, M., Jacqueminet, S., Sachon, C., Bosquet, F., Hartemann, A., & Grimaldi, A. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.01.005 · Cited by 13
Diagnosis and Management of Type 2 Diabetes and Prediabetes
Unger, J. (2007) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2007.07.007 · Cited by 14
Hod, M., Mathiesen, E. R., Jovanovič, L., McCance, D. R., Ivanišević, M., Durán-Garcia, S., Brøndsted, L., Nazeri, A., & Damm, P. (2013) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2013.783809 · Cited by 26
Liu, S., Liu, R., Chiang, Y., Song, L., Li, X., Jin, T., & Wang, Q. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00328.2011 · Cited by 11
Rosenstock, J., BAJAJ, H. S., Lingvay, I., & Heller, S. R. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003930 · Cited by 12
An overview of insulin therapy for the non‐specialist
Home, P. D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16280 · Cited by 13
Self-citationDedov, I. I., Shestakova, M. V., Абусуев, С. А., Valeeva, F. V., Verbovoy, A. F., Galstyan, G. R., Dogadin, S. A., Karpova, I. A., Mayorov, A. Y., Suntsov, Y. I., et al. (2010) · Diabetes Mellitus · doi:10.14341/2072-0351-6049 · Cited by 13
Spollett, G. R. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00721.x · Cited by 12
Solomon, M. D., Vijan, S. S., Forma, F. M., Conrad, R. M., Summers, N., & Lakdawalla, D. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.09.013 · Cited by 12
Diabetes Treatment, Part 3: Insulin and Incretins
Fowler, M. J. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.1.35 · Cited by 12
Detemir as a once-daily basal insulin in type 2 diabetes
Nelson (2011) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s19539 · Cited by 11
Bramlage, P., Bluhmki, T., Fleischmann, H., Kaltheuner, M., Beyersmann, J., Holl, R. W., & Danne, T. (2017) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000301 · Cited by 11
Achieving Glycemic Goals in Type 2 Diabetes
Bloomgarden, Z. T. (2006) · Diabetes Care · doi:10.2337/dc07-zb01 · Cited by 13
Efficacy and Safety of Insulin Detemir
Raskin, P. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(07)80005-3 · Cited by 14
Update on Insulin Management in Type 2 Diabetes
Neumiller, J. J., Odegard, P. S., & Wysham, C. (2009) · Diabetes Spectrum · doi:10.2337/diaspect.22.2.85 · Cited by 13
Initiating and Titrating Insulin in Patients With Type 2 Diabetes
Henske, J. A., Griffith, M. L., & Fowler, M. J. (2009) · Clinical Diabetes · doi:10.2337/diaclin.27.2.72 · Cited by 11
Bolli, G. B., Lucidi, P., Porcellati, F., & Fanelli, C. G. (2011) · Diabetes Care · doi:10.2337/dc11-s224 · Cited by 12
Rizvi, A. A., & Ligthelm, R. J. (2007) · Insulin · doi:10.1016/s1557-0843(07)80018-2 · Cited by 12
Raccah, D. (2006) · Insulin · doi:10.1016/s1557-0843(06)80036-9 · Cited by 13
Riddle, M. C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2576 · Cited by 11
Rhoads, G. G., Dain, M., Zhang, Q., & Kennedy, L. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01394.x · Cited by 10
Yki‐Järvinen, H., & Kotronen, A. (2013) · Diabetes Care · doi:10.2337/dcs13-2026 · Cited by 11
Hirsch, I. B., Buse, J. B., Leahy, J. L., McGill, J. B., Peters, A. L., Rodbard, H. W., Rubin, R. R., Skyler, J. S., Verderese, C. A., & Riddle, M. C. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12136 · Cited by 11
Farshchi, A., Aghili, R., Oskuee, M., Rashed, M., Noshad, S., Kebriaeezadeh, A., Kia, M., & Esteghamati, A. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0116-8 · Cited by 10
Safety and Effectiveness of Insulin Detemir in Different Age-Groups in the A1chieve Study
Malek, R., González-Gálvez, G., Naggar, N. E., Shah, S. N., Prusty, V., & Litwak, L. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0021-3 · Cited by 10
Treating Patients With Diabetes of Long Duration: GLP-1 Receptor Agonists and Insulin in Combination
Moghissi, E. S. (2014) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2014.086 · Cited by 10
Floch, J. P. L. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s7315 · Cited by 14
Bhargava, A., Chan, V., Kimball, E. S., & Oyer, D. S. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0342-9 · Cited by 10
The current schemes of insulin therapy: Pro and contra
Riddle, M. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108817 · Cited by 15
Choe, C. H., & Edelman, S. V. (2007) · PubMed · Cited by 12
Zhang, T., Ji, L., Gao, Y., Zhang, P., Zhu, D., Li, X., Ji, J., Zhao, F., Zhang, H., & Guo, X. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0111 · Cited by 11
Malesker, M. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.2.193 · Cited by 10
Bloomgarden, Z. T. (2007) · Diabetes Care · doi:10.2337/dc07-zb12 · Cited by 11
Dehghani, M., Sadeghi, M., Barzkar, F., Maghsoomi, Z., Janani, L., Motevalian, S. A., Loke, Y. K., Ismail‐Beigi, F., Baradaran, H. R., & Khamseh, M. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1286827 · Cited by 9
Marshall, M. (2007) · PubMed · Cited by 9
Safety and Efficacy of Modern Insulin Analogues
Yoo, H. J., Park, K. Y., Park, K. S., Ahn, K. J., Min, K. W., Park, J. H., Chang, S. A., Soo, B., Kim, D., Kim, Y., et al. (2013) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2013.37.3.181 · Cited by 9
Hendriksen, K. V., Jensen, T., Oturai, P., & Feldt‐Rasmussen, B. (2011) · Diabetologia · doi:10.1007/s00125-011-2345-8 · Cited by 9
Yale, J., Damcı, T., Kaiser, M., Karnieli, E., Khunti, K., Liebl, A., Baeres, F. M. M., Svendsen, A. L., & Ross, S. A. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-56 · Cited by 9
IDRIS, I. R., Gordon, J. P., Tilling, C., & Vora, J. P. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.991788 · Cited by 10
Gao, L., Zhang, P., Weng, J., Lu, J., Guo, X., Jia, W., Yang, W., Zou, D., Zhou, Z., Pan, C., et al. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13046 · Cited by 9
Hahr, A. J., & Molitch, M. E. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31815aeb79 · Cited by 10
Inhaled insulin: new formulation, new trial
Bailey, C. J., & Barnett, A. H. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60885-9 · Cited by 9
Liebl, A., Andersen, H., Svendsen, A. L., Vora, J. P., Yale, J., & the SOLVE Study Group (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12133 · Cited by 9
The treat-to-target A1C approach to control type 2 diabetes and prevent complications
White, R. D. (2007) · Advances in Therapy · doi:10.1007/bf02848777 · Cited by 10
Pollock, R. F., Chubb, B., Valentine, W. J., & Heller, S. R. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s156739 · Cited by 10
Gough, S. C. L., & Narendran, P. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch27 · Cited by 10
Cost–effectiveness of insulin detemir: a systematic review
Suh, D., & Aagren, M. (2011) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.73 · Cited by 10
Insulin analogs for the management of type 2 diabetes
Taylor, J. R., & Campbell, K. M. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110381 · Cited by 8
Wilding, J. P. H., & Bain, S. C. (2015) · Diabetic Medicine · doi:10.1111/dme.13021 · Cited by 8
Wang, W., Yan, X., Cheng, Z., Zhang, Q., Wang, R., Deng, Y., Ma, J., & Zhu, D. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15263 · Cited by 8
Insulin degludec is a new ultra-long-acting insulin analogue
Dedov, I. I., & Shestakova, M. V. (2014) · Diabetes Mellitus · doi:10.14341/dm2014291-104 · Cited by 8
Echtay, A. S., Tsur, A., Hasan, M. I., Abu-Hijleh, M. O., Khatib, N. A., Andari, E., Atallah, P., Qureshi, S., Zafar, J., Sandalci, L., et al. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0041-z · Cited by 8
Bi, Y., Li, X., Yang, D., Hao, Y., Liang, H., Zhu, D., & Weng, J. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2011.00187.x · Cited by 8
Imam, S. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-800093-9.00003-x · Cited by 8
Hypoglycaemia in Type 2 Diabetes and in Elderly People
Zammitt, N. N., & Frier, B. M. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch12 · Cited by 9
Thomsen, R. W., Baggesen, L. M., Søgaard, M., Pedersen, L. H., Nørrelund, H., Buhl, E. S., Haase, C., & Johnsen, S. P. (2016) · Diabetic Medicine · doi:10.1111/dme.13168 · Cited by 8
Implementing Treatment Guidelines for Type 2 Diabetes in Primary Care
Brunton, S. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.03.1985 · Cited by 8
Korsatko, S., Glettler, K., Olsen, K. J., Wutte, A., Bock, G., Koehler, G., Mader, J. K., Semlitsch, B., & Pieber, T. R. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12016 · Cited by 8
Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made?
Kalra, S. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.155407 · Cited by 8
Pérez, A., Elrod, S., & Sánchez, J. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715593813 · Cited by 7
Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial
Sélam, J.-L., & Meneghini, L. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0007-8 · Cited by 8
Philis‐Tsimikas, A. (2008) · Patient Preference and Adherence · doi:10.2147/ppa.s3293 · Cited by 7
Philis‐Tsimikas, A., Lane, W. S., Pedersen‐Bjergaard, U., Wysham, C., Bardtrum, L., Østoft, S. H., & Heller, S. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13954 · Cited by 7
Progression of Type 2 Diabetes and Insulin Initiation
Rolla, A. R. (2011) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)30296-0 · Cited by 7
Proteomic Changes to the Updated Discovery of Engineered Insulin and Its Analogs: Pros and Cons
Hanif, N., Wu, H., Xu, P., Li, Y., Bibi, A., Zulfiqar, A., Iqbal, M. Z., Tahir, M., Zhang, X., & Ali, A. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44020059 · Cited by 7
Is There a Rationale for Insulin Therapy in Pre-Diabetic Individuals?
Schwartz, S. L. (2006) · Treatments in Endocrinology · doi:10.2165/00024677-200605060-00007 · Cited by 8
Common crossroads in diabetes management
Valitutto, M. (2008) · Osteopathic Medicine and Primary Care · doi:10.1186/1750-4732-2-4 · Cited by 8
Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
Young, J. R., & McAdam-Marx, C. (2010) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s5330 · Cited by 8
Metadata
- Authors
- Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group
- Affiliations
- Aarhus University Hospital (DK)
- Leicester Royal Infirmary (GB)
- Out-Patient Clinic, NZOZ Eskulap, Gniewkowo, Poland
- Out-Patient Clinic, Novo Nordisk, Bagsværd, Denmark
- Novo Nordisk (Denmark) (DK)
- Newcastle University (GB)
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2006-06-01
- Volume
- 29
- Issue
- 6
- Pages
- 1269-1274
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2149194615
- Cited by
- 627
- References
- 36
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 11 · 2018: 16 · 2017: 15 · 2016: 24 · 2015: 31 · 2014: 44 · 2013: 59 · 2012: 55
- FWCI
- 48.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin detemir, NPH insulin, basal insulin, type 2 diabetes, insulin-naive patients, oral glucose-lowering agents, adjunctive therapy, glycemic control, HbA1c, hypoglycemia, nocturnal hypoglycemia, weight gain
- MeSH terms
- Insulin Detemir, Administration, Oral, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Weight Gain, Body Mass Index, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.